Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; ISA 101 (Primary)
  • Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms OpcemISA
  • Sponsors ISA Pharmaceuticals

    • Most Recent Events

    • 12 Sep 2024 This trial has been completed in France , according to European Clinical Trials Database record.
    • 04 Jun 2024 Results assessing the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer patients were presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 19 May 2024 This trial has been completed in Czechia, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top